Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Michael Shapira, MD Haddassah Medical Center Interview date: April 18, 2014 Summary Dr. Shapira shares work done to test a myeloma vaccine from Vaxil called ImMucin that targets the MUC1 oncoprotein, found in about 70% of myeloma patients. This vaccine was used in an early clinical trial to test safety, but the study results look promising, even when used without other therapies. He also describes his work to increase the upper age limit effectively for transplantation including autologous and allogenic and how he has been able to reduce graft vs. host side effects of allogeneic transplant with multiple strategies. The live mPatient Myeloma Radio podcast with Dr. Michael Shapira
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113
Support@healthtree.org
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.